Hormone Therapy (ADT) along with the chemotherapy drug Taxotere (docetaxel) and Estramustine improves survival in men with high risk, localized castration-resistant prostate cancer over ADT alone.
Recent research has concluded that for men who are going to use early chemotherapy along with hormone therapy, chemotherapy should be delayed, allowing at least three weeks to pass after starting the hormone therapy before commencing the chemotherapy treatments.
Chemotherapy has a bad reputation because of its side effects. This reputation has contributed to many men deciding not to use it in their treatment protocol. Is this a mistake, we present a small amount of empirical evidence that this can be an error.